Certolizumab pegol in the treatment of Takayasu arteritis

Novikov P. I., Smitienko I. O., Sokolova M. V., Alibaz-Oner F., Kaymaz-Tahra S., Direskeneli H., ...Daha Fazla

RHEUMATOLOGY, cilt.57, sa.12, ss.2101-2105, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 57 Sayı: 12
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1093/rheumatology/key197
  • Dergi Adı: RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.2101-2105
  • Anahtar Kelimeler: TNF inhibitors, certolizumab pegol, Takayasu arteritis, ANTIRHEUMATIC DRUGS, CASES SERIES, MULTICENTER, PREGNANCY, INHIBITORS, INFLIXIMAB, EFFICACY, CRITERIA, STANDARD, ALPHA
  • Marmara Üniversitesi Adresli: Evet

Özet

Objectives. Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA).